By: Dylan Sikes - AllPennyStocks.com News

Wednesday, May 11, 2016

According to a report from RNCOS on the U.S. Generic Drug Market Outlook, the U.S. generics market was worth $43.5 billion in 2013. RNCOS expects this market to grow at a CAGR of around 11% until 2018. RNCOS noted in its report that the U.S. generics market is witnessing major developments in terms of new product categories that are attracting huge investments from both public and private players. RNCOS expects the U.S. generics market to showcase healthy growth potential in various therapy segments such as oncology, respiratory, thyroid, ulcers as well as cholesterol disorders in the coming years. The growth in these areas will be the result of patent expirations of a number of the major drugs in the next few years, the report added.

The outlook for the generics market augurs well for Sunshine Biopharma Inc. (OTCQB:SBFM), a pharmaceutical company focusing on the research, development and commercialization of drugs for the treatment of various forms of cancer.

SBFM shares have surged in trading today. At last check, the stock was trading 26.11% higher at $0.0114 on volume of 4.68 million, which is significantly above the daily average volume of 1.65 million. SBFM shares have gained more than 41% in the last month.

Sunshine Biopharma shares are rallying in trading today after the company announced that it has signed a Cross Referencing Agreement with a major pharmaceutical company for Anastrozole, a prescription generic drug for treatment of Breast Cancer. Sunshine will market and sell this new pharmaceutical product under its own label.

SBFM said that it is currently in the process of securing a Drug Identification Number ("DIN") for its own label of Anastrozole from Health Canada. The Company is also working on obtaining a Drug Establishment License ("DEL") from Health Canada. After receiving the DIN, the company will be able to accept orders for its SBI-Anastrozole. The company expects to build a portfolio of "SBI" label Generic Pharmaceuticals over time. Revenues from the sales of Generic Products are intended to be used to finance the Company's proprietary drug development program including Adva-27a, the Company's flagship anticancer compound. A Topoisomerase II inhibitor, Adva-27a is a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Breast Cancer cells, Pancreatic Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.

Copyright © 2016 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.